qtr-three earnings per share $num-two.
sees fy non-gaap revenue growth between num-one% and num-two%.
qtr-three sales $num-one million versus refinitiv ibes estimate of $879.9 million.
qtr-three non-gaap earnings per share $num-two.
sees fy year-six covid-related sales $num-one million to $2.2 million versus prior guidance of $3.3 million to 3.0 million.
qtrly sales increased num-one% on a currency neutral basis.
qtr-three operating income $num-one million, or num-two% of sales.
qtr-three sales $num-one million versus refinitiv ibes estimate of $452.7 million.
qtr-three sales rose num-three percent to $num-one million.
qtr-three non-gaap gross margin of num-one% versus num-two% in qtr-two of year-five.
qtr-three research and development expense of $num-one million, or num-two% of sales, compared to $num - three million, num-four% of year-five.
qtr-three sales rose num-two percent to $num-three billion.
sees fy non-gaap gross margin in range of num-one% to num-two%.
qtr-three revenue rose num-two percent to $num-one million.
sees fy adjusted ebitda margin in range of num-one% to num-two%.
sees qtr-three digital pcr revenue $num-one billion to $num-$num-two billion.
